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RESUMO – A hiperpigmentação cutânea com fotodistribuição pode ser despoletada por vários medicamentos. Descrevemos 
o caso de uma mulher de 69 anos que desenvolveu hiperpigmentação facial após tratamento com olmesartan medoxo-
milo-hidroclorotiazida e melhorou após a sua suspensão, sugerindo fortemente que a hiperpigmentação foi induzida pelo 
fármaco. O olmesartan medoxomilo-hidroclorotiazida deve ser adicionado à lista de medicamentos que podem induzir hi-
perpigmentação cutânea com fotodistribuição.   
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Facial Hyperpigmentation Induced by 
Combination Therapy with Olmesartan Medoxomil- 
-Hydrochlorothiazide  
ABSTRACT – Photodistributed hyperpigmentation has been associated with several drugs. We describe a 69-year-old 
woman who developed facial skin hyperpigmentation starting after treatment with a combination of olmesartan medoxomil 
and hydrochlorothiazide and improving following its withdrawal, suggesting drug-induced dyspigmentation. Olmesartan 
medoxomil-hydrochlorothiazide should be added to the list of drugs that can induce photodistributed cutaneous hyperpig-
mentation.
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INTRODUCTION
APhotodistributed hyperpigmentation has been re-
ported in association with several drugs.1 Olmesartan 
medoxomil-hydrochlorothiazide is a combination of an 
angiotensin II receptor antagonist and a thiazide diuretic 
used to treat arterial hypertension. We describe a patient 
who developed skin hyperpigmentation while being trea-
ted with a combination of olmesartan medoxomil-hydro-
chlorothiazide.
CASE REPORT
A 69-year-old woman was referred to our clinic with 
a two-month history of facial hyperpigmentation. Her 
medical history was unremarkable except for arterial 
hypertension diagnosed four months earlier treated with 
olmesartan medoxomil-hydrochlorothiazide (40g/12.5 
mg) for three months. She denied associated symptoms 
such as burning sensation or pruritus, as well as previous 
erythema or scaling in the area. Physical examination 
showed a slate-gray hyperpigmentation on the face and 
sides of the neck sparing the cutaneous folds and mucous 
membranes (Fig. 1a-b). Laboratory investigations were 
unrevealing including the ACTH stimulation test. Histopa-
thology revealed pigmentary incontinence with multiple 
melanophages dispersed in the dermis.
Photodistributed hyperpigmentation caused by an-
tihypertensive treatment was suspected based on the cli-
nical and histological features. Photoprotection along 
with replacement of olmesartan medoxomil-hydrochlo-
rothiazide with amlodipine and nebivolol resulted in 
significant fading of the pigmentation at three months 
follow-up (Fig. 1c).
DISCUSSION
Drug-induced skin pigmentation is estimated 
to account for 10% to 20% of all cases of acquired 
Revista SPDV 76(3) 2018; Hyperpigmentation induced by Olmesartan-HTZ; Costa-Silva M, César A, Gomes NP, Fernandes MS, Azevedo F.
Figure 1 - Slate-gray hyperpigmentation on the face (A) sparing the cutaneous folds (B). Pigmentation fading 3 months after stopping olmesartan 
medoxomil-hydrochlorothiazide (C).
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hyperpigmentation.2 Drugs that have been reported to 
induce skin and/or mucous membrane discoloration in-
clude antimalarials, amiodarone, cytotoxic drugs, nons-
teroidal anti-inflammatory drugs, tetracyclines, heavy 
metals, and psychotropic drugs.1-5 Antihypertensive drugs 
are one of the most commonly prescribed drugs, but re-
ports of drug-related cutaneous hyperpigmentation are 
notably uncommon. In this respect, most cases are asso-
ciated with diltiazem and amlodipine.3,6,7 Recently, Gimé-
nez-García,3 described for the first time dyspigmentation 
induced by combination therapy with telmisartan-hydro-
chlorothiazide. To the best of our knowledge, no case of 
cutaneous hyperpigmentation associated with olmesartan 
medoxomil-hydrochlorothiazide has been formally repor-
ted to date. 
The pathogenesis of drug-induced dyspigmentation 
has not been fully elucidated. It relates to specific cha-
racteristics of the causative agent and can involve a der-
mal accumulation of melanin, of the culprit drug itself or 
drug complexes; synthesis of special pigments under the 
direct influence of the drug, such as lipofuscin; or dermal 
deposition of iron owing to drug-induced damage to der-
mal vessels.1,2 Clinical features are variable, with a large 
range of patterns, colors, and distributions.3 Lesions are 
often accentuated in sun-exposed areas as was the case 
in our patient.3
Treatment includes sun-avoidance measures and in-
terruption of the offending drug, but Q-switched alexan-
drite laser therapy and topical immunomodulators have 
been successfully used in some cases.2,6,8 With these inter-
ventions, in most reported cases, improvement is slowly 
achieved. Nevertheless, hyperpigmentation may be per-
manent in some cases.1,2
Hyperpigmentation starting after olmesartan medoxo-
mil-hydrochlorothiazide therapy and improving following 
its withdrawal strongly suggests that the dyspigmentation 
was drug-induced. Furthermore, both the clinical and his-
tologic findings are similar with previous reports on this 
type of reaction with other antihypertensive drugs. 
Olmesartan medoxomil-hydrochlorothiazide should 
be added to the list of drugs that can induce photodis-
tributed cutaneous hyperpigmentation. Antihypertensive 
drugs, must be considered in the differential diagnosis 
of unexplained cutaneous hyperpigmentation with a clear 
photodistribution.
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